10-QPeriod: Q2 FY2016

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2016

Filed August 2, 2016For Securities:DXCM

Summary

DexCom Inc. reported strong revenue growth for the second quarter and first half of 2016, with product revenue increasing by 47.8% and 48.5% year-over-year, respectively. This growth was driven primarily by increased sales volume of disposable sensors and durable systems, indicating continued expansion of their customer base for the G4 PLATINUM and G5 Mobile continuous glucose monitoring (CGM) systems. Despite revenue growth, the company continues to operate at a net loss, with an accumulated deficit of $594.8 million as of June 30, 2016. Management believes current working capital and available credit are sufficient to fund operations through at least June 30, 2017, though future financing needs are acknowledged. The company also highlighted significant increases in operating expenses, particularly in Research & Development and Selling, General & Administrative, reflecting investments in growth, commercialization, and international expansion. A notable event was the customer notification regarding audible alarms and alerts on G4 PLATINUM and G5 Mobile receivers, classified as a voluntary Class 1 recall, which impacted cost of sales due to excess and obsolete inventory charges.

Financial Statements
Beta
Revenue$137.30M
Cost of Revenue$51.80M
Gross Profit$85.50M
R&D Expenses$36.30M
SG&A Expenses$69.30M
Operating Expenses$105.60M
Operating Income-$20.10M
Interest Expense$100K
Net Income-$20.20M
EPS (Basic)$-0.06
Shares Outstanding (Basic)334.40M
Shares Outstanding (Diluted)334.40M

Key Highlights

  • 1Product revenue increased by 47.8% to $137.3 million for Q2 2016 and by 48.5% to $253.5 million for the first six months of 2016, compared to the prior year periods.
  • 2Gross profit increased by 29.5% to $85.5 million for Q2 2016 and by 42.7% to $160.6 million for the first six months of 2016.
  • 3Operating expenses, particularly R&D and SG&A, saw significant increases (R&D +48.8% Q2, +54.9% H1; SG&A +53.3% Q2, +55.3% H1) reflecting investment in growth and expansion.
  • 4The company continues to operate at a net loss, reporting a net loss of $20.2 million for Q2 2016 and $39.4 million for the first six months of 2016.
  • 5DexCom entered into a $200 million revolving credit agreement in June 2016, enhancing its liquidity position.
  • 6A voluntary Class 1 recall was issued for G4 PLATINUM and G5 Mobile receivers concerning audible alarms and alerts, impacting cost of sales due to inventory charges.
  • 7The company stated its belief that existing liquidity and credit facilities are sufficient to fund operations through at least June 30, 2017.

Frequently Asked Questions

Revenue growth was primarily driven by an increase in sales volume of disposable sensors and durable continuous glucose monitoring (CGM) systems, specifically the G4 PLATINUM and G5 Mobile models. This indicates successful expansion of DexCom's customer base and ongoing adoption of their technology.

DexCom continued to report a net loss due to significant investments in Research and Development (R&D) and Selling, General, and Administrative (SG&A) expenses. These increases were attributed to supporting revenue growth, commercialization efforts, international expansion, and increased share-based compensation, reflecting the company's strategy to invest heavily in future growth rather than immediate profitability.

As of June 30, 2016, DexCom had $115.6 million in cash, cash equivalents, and marketable securities, along with $167.1 million in working capital. The company also secured a $200 million revolving credit facility in June 2016. Management believes these resources are sufficient to fund operations through at least June 30, 2017, acknowledging potential future capital needs.

DexCom issued a voluntary Class 1 recall notice for audible alarms and alerts on its G4 PLATINUM and G5 Mobile receivers. This issue led to charges for excess and obsolete receiver inventory, impacting the cost of sales.